Summary
14.51 -0.26(-1.76%)06/28/2024
BLCO (BLCO)
BLCO (BLCO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.76 | -8.05 | -17.53 | -0.58 | -20.70 | -23.51 | 0.00 | -66.51 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 14.51 | |
| Open | 14.75 | |
| High | 14.92 | |
| Low | 14.41 | |
| Volume | 630,971 | |
| Change | -0.26 | |
| Change % | -1.76 | |
| Avg Volume (20 Days) | 533,901 | |
| Volume/Avg Volume (20 Days) Ratio | 1.18 | |
| 52 Week Range | 13.16 - 21.95 | |
| Price vs 52 Week High | -33.90% | |
| Price vs 52 Week Low | 10.26% | |
| Range | -3.13 | |
| Gap Up/Down | 0.10 | |
Fundamentals | ||
| Market Capitalization (Mln) | 5,096 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
06/17 07:00 EST - businesswire.com
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from.
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from.
06/10 07:00 EST - businesswire.com
Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company's proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day co.
Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company's proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day co.
06/03 07:00 EST - businesswire.com
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* “We offer dry eye sufferers a wide array of options tha.
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* “We offer dry eye sufferers a wide array of options tha.
05/29 16:30 EST - businesswire.com
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28.
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28.
05/28 06:59 EST - businesswire.com
Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “enVista Envy is the next step in the dram.
Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “enVista Envy is the next step in the dram.
05/01 13:38 EST - seekingalpha.com
Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Robbie Marcus - JPMorgan Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Matt Miksic - Barclays Doug Miehm - RBC Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Robbie Marcus - JPMorgan Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Matt Miksic - Barclays Doug Miehm - RBC Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
05/01 06:58 EST - businesswire.com
Bausch + Lomb Announces First-Quarter 2024 Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. “Outperformance from each of our business units and solid results across geographies led to an impressive quarter and once again demonstrated our quality of growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our key franchises continue to deliver, and a focu.
Bausch + Lomb Announces First-Quarter 2024 Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. “Outperformance from each of our business units and solid results across geographies led to an impressive quarter and once again demonstrated our quality of growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our key franchises continue to deliver, and a focu.
04/29 07:00 EST - businesswire.com
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the compa.
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the compa.
04/25 08:30 EST - businesswire.com
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of a novel daily nutritional supplement formulated to address the symptoms of dry eyes.1 Bausch + Lomb expects to launch the supplement, which features a proprietary blend of ingredient.
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of a novel daily nutritional supplement formulated to address the symptoms of dry eyes.1 Bausch + Lomb expects to launch the supplement, which features a proprietary blend of ingredient.
04/24 11:06 EST - zacks.com
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/18 07:00 EST - businesswire.com
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue® Eye Care Recycling programs have collected 84,343,540 units, or 510,116 pounds, of used contact lenses, eye care and lens care materials in the U.S., which is greater than the weight of the Statue of Liberty.1 “Eye care professionals, patients and consumers have helped us collect hund.
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue® Eye Care Recycling programs have collected 84,343,540 units, or 510,116 pounds, of used contact lenses, eye care and lens care materials in the U.S., which is greater than the weight of the Statue of Liberty.1 “Eye care professionals, patients and consumers have helped us collect hund.
04/15 12:00 EST - businesswire.com
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of.
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of.
04/08 12:41 EST - zacks.com
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
03/25 13:01 EST - zacks.com
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
03/21 12:41 EST - zacks.com
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
03/20 13:21 EST - zacks.com
Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
02/21 13:07 EST - seekingalpha.com
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
02/21 10:31 EST - zacks.com
Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
02/21 08:27 EST - marketwatch.com
Bausch & Lomb's stock soars 11% after earnings beat
Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
Bausch & Lomb's stock soars 11% after earnings beat
Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.